Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $195.7 million.

  • Haemonetics' Receivables - Net fell 766.32% to $195.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $195.7 million, marking a year-over-year decrease of 766.32%. This contributed to the annual value of $202.7 million for FY2025, which is 189.05% down from last year.
  • Haemonetics' Receivables - Net amounted to $195.7 million in Q4 2025, which was down 766.32% from $207.1 million recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Receivables - Net peaked at $213.5 million during Q3 2024, and registered a low of $127.6 million during Q2 2021.
  • Moreover, its 5-year median value for Receivables - Net was $180.1 million (2022), whereas its average is $179.9 million.
  • As far as peak fluctuations go, Haemonetics' Receivables - Net crashed by 2279.08% in 2021, and later soared by 2494.69% in 2022.
  • Haemonetics' Receivables - Net (Quarter) stood at $141.3 million in 2021, then increased by 28.16% to $181.1 million in 2022, then increased by 16.85% to $211.6 million in 2023, then increased by 0.16% to $211.9 million in 2024, then dropped by 7.66% to $195.7 million in 2025.
  • Its Receivables - Net was $195.7 million in Q4 2025, compared to $207.1 million in Q3 2025 and $200.8 million in Q2 2025.